Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3834 Target Snapshot

Cytoplasmic tyrosine-protein kinase BMX · SINGLE PROTEIN · Homo sapiens

1,391Compounds
491Assays
17Approved Drugs
669.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P51813. Use UniProt P51813 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P51813 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cytoplasmic tyrosine-protein kinase BMX as ChEMBL target CHEMBL3834, mapped to UniProt P51813. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cytoplasmic tyrosine-protein kinase BMX
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3834
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P51813
Cytoplasmic tyrosine-protein kinase BMX
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cytoplasmic tyrosine-protein kinase BMX is the right protein anchor across sources, using UniProt P51813 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCytoplasmic tyrosine-protein kinase BMX
UniProt AccessionP51813
Component TypeProtein
Sequence Length675 aa

Cytoplasmic tyrosine-protein kinase BMX

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Cytoplasmic tyrosine-protein kinase BMX, mapped to UniProt P51813. Sequence length is 675 aa.

Mapped IDP51813
Review nameCytoplasmic tyrosine-protein kinase BMX
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

17
Approved
7
Phase III
14
Phase II
4
Phase I
Assay Mix

Activity Type Distribution

IC50482.0
KI7.0
EC5010.0
KD170.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1643976 9.4 IC50 0.4 Preclinical
CHEMBL1873475 9.4 IC50 0.4 Approved
CHEMBL3647964 9.4 IC50 0.4 Preclinical
CHEMBL5757288 9.39 IC50 0.41 Preclinical
CHEMBL5189379 9.22 IC50 0.6 Preclinical
CHEMBL3936761 9.21 IC50 0.62 Approved
CHEMBL3290148 9.15 IC50 0.71 Preclinical
CHEMBL3182647 9.1 IC50 0.8 Preclinical
CHEMBL4560385 9.05 IC50 0.9 Preclinical
CHEMBL288441 9.0 IC50 1.0 Approved
Distribution

pChEMBL Value Distribution

26
5.0
43
5.5
51
6.0
50
6.5
58
7.0
86
7.5
50
8.0
30
8.5
26
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

RITLECITINIB
CHEMBL4085457
Approved 2023
TIRABRUTINIB
CHEMBL4071161
Approved 2020
ZANUBRUTINIB
CHEMBL3936761
Approved 2019
ACALABRUTINIB
CHEMBL3707348
Approved 2017
IBRUTINIB
CHEMBL1873475
Approved 2013
BOSUTINIB
CHEMBL288441
Approved 2012
DASATINIB
CHEMBL5416410
Approved 2006
Assay Landscape

Assay Landscape

491
Total Assays
348
Tested Compounds
3
Assay Types
Binding — 475 assays, 348 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 351 204 7.4
assay format 76 89 6.8
cell-based format 47 55 6.7
subcellular format 1 0
Functional — 11 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 10 2 6.3
assay format 1 0
ADME — 5 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 3 1 7.4
cell-based format 1 0
single protein format 1 2 9.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine